Cadila Healthcare gets USFDA approval to market Topiramate

Cadila Healthcare has informed that Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Topiramate tablets in strengths of 25mg, 50mg, 100mg, and 200mg.

The drug falls in the anti-epileptic segment. The sales of Topiramate tablets as per NDC Health were estimated at $ 2.6 billion in 2008.

The group now has 42 ANDA approvals and has so far filed 83 ANDAs since the commencement of filing process in FY 2003-04.